


PHARMACEUTICAL 2020

## Strongbridge Biopharma plc Rank 165 of 362







## Strongbridge Biopharma plc Rank 165 of 362

The relative strengths and weaknesses of Strongbridge Biopharma plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Strongbridge Biopharma plc compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 99% points. The greatest weakness of Strongbridge Biopharma plc is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 84% points.

The company's Economic Capital Ratio, given in the ranking table, is -149%, being 154% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	83,543
Cost of Goods Sold	0
Intangible Assets	32,366
Liabilities, Current	24,293
Liabilities, Non-Current	1,080
Other Assets	1,438
Other Compr. Net Income	3.0
Other Expenses	10,612
Other Liabilities	20,074
Other Net Income	19,410
Property and Equipment	291
Research and Development	30,903
Revenues	21,712
Selling, General and Administrative Expense	49,058

Output Variable	Value in 1000 USD
Assets	117,638
Liabilities	45,447
Expenses	90,573
Stockholders Equity	72,191
Net Income	-49,451
Comprehensive Net Income	-49,450
Economic Capital Ratio	-149%

